Intrepid Financial Planning Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Intrepid Financial Planning Group’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$66.9K	Hold	30,150	–	–	0.02%	133
2026 Q2	$80.5K	Hold	30,150	–	–	0.03%	134
2026 Q1	$71.2K	Hold	30,150	–	–	0.03%	123
2025 Q4	$63.6K	Hold	30,150	–	–	0.02%	120
2025 Q3	$51.6K	Hold	30,150	–	–	0.02%	126
2025 Q2	$35K	Hold	30,150	–	–	0.01%	121
2025 Q1	$33.2K	Hold	30,150	–	–	0.02%	116
2024 Q4	$51.9K	Hold	30,150	–	–	0.02%	119
2024 Q3	$74.8K	Hold	30,150	–	–	0.03%	121
2024 Q2	$73K	Hold	30,150	–	–	0.03%	122
2024 Q1	$122K	Hold	30,150	–	–	0.05%	120
2023 Q4	$116K	Hold	30,150	–	–	0.06%	114
2023 Q3	$125K	Buy	30,150 +10,000	+50%	+$61.8K	0.06%	110
2023 Q2	$96.9K	Sell	20,150 -10,000	-33%	-$47.9K	0.05%	116
2023 Q1	$122K	Buy	30,150 +20,150	+202%	+$105K	0.06%	113
2022 Q4	$54K	Buy	+10,000	New	+$67.2K	0.03%	112

Other funds holding ABOS

Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Knollwood Investment Advisory Hunt Valley, Maryland $1.18B AUM 37.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $33B AUM 30.04% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $36.2B AUM 20.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Intrepid Financial Planning Group's ABOS Position: Q3 2026 in Review

Intrepid Financial Planning Group held its Acumen Pharmaceuticals (ABOS) position steady in Q3 2026 at 30,150 shares worth $66.9K. The position accounts for 0.02% of the portfolio, ranked #133.

Intrepid Financial Planning Group first reported a position in ABOS in Q4 2022 and has held it in 16 quarters since. The position peaked at $125K in Q3 2023. 67 funds tracked by Wall St. Rank hold ABOS as of Q3 2026.

Intrepid Financial Planning Group held 30,150 shares of Acumen Pharmaceuticals worth $66.9K as of Q3 2026.
Intrepid Financial Planning Group left its Acumen Pharmaceuticals share count unchanged in Q3 2026.
Acumen Pharmaceuticals made up 0.02% of Intrepid Financial Planning Group's portfolio in Q3 2026, its #133 holding.
Intrepid Financial Planning Group first reported a position in Acumen Pharmaceuticals in Q4 2022 and has held it in 16 quarters since.
Intrepid Financial Planning Group's Acumen Pharmaceuticals position peaked at $125K in Q3 2023.
67 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2026.

Based on Intrepid Financial Planning Group's 13F filing for Q3 2026, filed 12 Nov 2026.